Gilead could be sitting on close to $20 billion in untapped stock market value, provided it has success with a potential new coronavirus vaccine.<\/p>\n
Oppenheimer analyst Hartaj Singh estimates that a worldwide release of remdesivir currently in Phase 3 trial for Gilead could lead to $500 million in yearly pandemic sales stocking. The analyst assumes the coronavirus pill would cost $50 to $100 per patient compared to $16 a pill for flu treatment Tamiflu in the U.S. Singh sees the pill reaching 5 million to 10 million people in terms of pandemic stock-piling.<\/p>\n
Gileads trials of remdesivir include one targeting patients with severe manifestations of coronavirus. The other focuses on patients with more moderate affects from COVID-19.<\/p>\n
Assuming such a conservative model, successful Phase 3 outcomes in the moderate patients are worth 5% to 10% to Gilead. If both Phase 3's are successful, we foresee greater pricing leverage in developed markets and higher stocking; leading to a 10% to 20% valuation bump. Clearly a pandemic stockpiling of remdesivir (like Tamiflu) is where Gilead stock benefits most. Acute treatment for millions of patients would be more a harbinger of a Street meltdown, Singh writes.<\/p>\n
Using the aggressive side of Singhs estimates for remdesivir, Gileads market cap could approach $115 billion versus $94 billion today.<\/p>\n
The market has begun to lock in on Gilead and to a lesser extent Moderna as coronavirus vaccine winners.<\/p>\n
Shares of Gilead has rocketed 10% higher over the past month while the broader stock market has gone in the tank on fears of a global economic slowdown. On the other hand, Moderna which has a coronavirus vaccine in Phase 1 has seen its stock skyrocket 31% in the past month.<\/p>\n
[Take our quick poll: Do you think the stock market has bottomed?]<\/p>\n
Brian Sozzi is an editor-at-large and co-anchor of The First Trade at Yahoo Finance. Follow Sozzi on Twitter @BrianSozzi and on LinkedIn.<\/p>\n
Read the latest financial and business news from Yahoo Finance<\/p>\n
Story continues<\/p>\n
Follow Yahoo Finance on Twitter, Facebook, Instagram, Flipboard, SmartNews, LinkedIn, YouTube, and reddit.<\/p>\n
<\/p>\n
See more here: <\/p>\n
Coronavirus vaccine could add billions in value to this one stock - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Gilead could be sitting on close to $20 billion in untapped stock market value, provided it has success with a potential new coronavirus vaccine. Oppenheimer analyst Hartaj Singh estimates that a worldwide release of remdesivir currently in Phase 3 trial for Gilead could lead to $500 million in yearly pandemic sales stocking. The analyst assumes the coronavirus pill would cost $50 to $100 per patient compared to $16 a pill for flu treatment Tamiflu in the U.S. Continue reading